De Gaulle Fleurance & Associés advises Lysogene for its funding by the BPI
Biotech Paris, December 2nd ,2021 The biopharmaceutical company, Lysogene, has obtained a €4.3 million non-dilutive funding from Bpifrance to support its development. This funding is composed ...